Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Nov;11(11):355-357.
doi: 10.14740/jmc3561. Epub 2020 Sep 23.

Synthetic Cannabinoids: An Emerging Cause of Coagulopathy

Shakir Ullah  1 , Amna M Chaudhary  2 , Khalid Nawab  3 , Ravi Athwani  3 , Amandeep Singh  3
Affiliations
Case Reports

Synthetic Cannabinoids: An Emerging Cause of Coagulopathy

Shakir Ullah et al. J Med Cases. 2020 Nov.

Abstract

Synthetic cannabinoids-associated coagulopathy cases are on the rise but are usually undetected in clinical settings due to less awareness among physicians and the lack of available literature on the subject. Patient may also not volunteer information about the use of such substances therefore detailed history is important. We present a case of a patient found to have coagulopathy of unclear cause as patient did not report the use of synthetic cannabinoid initially.

Keywords: Coagulopathy; Marijuana; Synthetic cannabinoids.

PubMed Disclaimer

Conflict of interest statement

None to declare.

References

    1. Pacher P, Steffens S, Hasko G, Schindler TH, Kunos G. Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly. Nat Rev Cardiol. 2018;15(3):151–166. doi: 10.1038/nrcardio.2017.130. - DOI - PubMed
    1. Mensen VT, Vreeker A, Nordgren J, Atkinson A, de la Torre R, Farre M, Ramaekers JG. et al. Psychopathological symptoms associated with synthetic cannabinoid use: a comparison with natural cannabis. Psychopharmacology (Berl) 2019;236(9):2677–2685. doi: 10.1007/s00213-019-05238-8. - DOI - PMC - PubMed
    1. Statement from FDA warning about significant health risks of contaminated illegal synthetic cannabinoid products that are being encountered by FDA | FDA. https://www.fda.gov/news-events/press-announcements/statement-fda-warnin.... Accessed July 27, 2020.
    1. Castaneira G, Rojas K, Galili Y, Field Z, Perez-Perez A, Madruga M, Carlan SJ. Idiopathic thrombocytopenic purpura induced by synthetic cannabinoid. J Addict Med. 2019;13(3):235–236. doi: 10.1097/ADM.0000000000000485. - DOI - PubMed
    1. Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014;144:12–41. doi: 10.1016/j.drugalcdep.2014.08.005. - DOI - PMC - PubMed

Publication types